TheraRadar
← Back
Data updated: Jun 28, 2026

SANOFI-AVENTIS US

Biotech
MetabolicOncologyCardiovascular Execution: Good

SANOFI-AVENTIS US is a biotechnology company focused on Metabolic, Oncology, Cardiovascular. Key products include ADLYXIN.

2016
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
4 Biologics

FDA Novel Drug Designations

(2016)
1 Novel 1 Priority Review
See 1 novel approval →
2016 ADLYXIN (LIXISENATIDE) Priority Review

SANOFI-AVENTIS US at a Glance

  • Fast trial execution (19 months median completion)

SANOFI-AVENTIS US's Key Drugs

SANOFI-AVENTIS US's core commercial portfolio centers on ADLYXIN, SOLIQUA 100/33, ADMELOG, spanning Metabolic and Oncology — its most strategically important drugs approved in the last 15 years.

ADLYXIN
Metabolic

Type 2 Diabetes

GLP1R Approved 2016
SOLIQUA 100/33
Metabolic

Type 2 Diabetes

GLP1R Approved 2016
ADMELOG
Metabolic

Diabetes

Approved 2017
ADMELOG SOLOSTAR
Metabolic

Diabetes

Approved 2017

SANOFI-AVENTIS US's Recent FDA Approvals

New NDA/BLA approvals for SANOFI-AVENTIS US over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SANOFI-AVENTIS US's Therapeutic Areas

SANOFI-AVENTIS US's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Oncology, across 4 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 39%
4 drugs Phase 3: 69 Phase 2: 11 Phase 1: 99
Oncology 29%
0 drugs Phase 3: 32 Phase 2: 49 Phase 1: 88
Cardiovascular 13%
0 drugs Phase 3: 27 Phase 2: 8 Phase 1: 15
Immunology 11%
0 drugs Phase 3: 14 Phase 2: 21 Phase 1: 19
Respiratory 9%
0 drugs Phase 3: 15 Phase 2: 14 Phase 1: 9

SANOFI-AVENTIS US Pipeline Snapshot

SANOFI-AVENTIS US has 490 active clinical programs from ClinicalTrials.gov — 157 Phase 3, 103 Phase 2 and 230 Phase 1.

157
Phase 3
103
Phase 2
230
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ADLYXIN leads revenue
  • • 4 key drugs tracked

Trial Catalysts

  • • Metabolic pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 224/312 completed
  • • Speed: 19 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges